{"id":"W2255445538","doi":"10.1007/s11938-016-0085-z","title":"Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review","year":2016,"lang":"en","type":"article","venue":"Current Treatment Options in Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"AbbVie Canada; National Institutes of Health; Ironwood Pharmaceuticals, Incorporated","keywords":"Medicine; Inflammatory bowel disease; Ulcerative colitis; Drug; Dosing; Therapeutic drug monitoring; Antibody; Disease; Clinical trial; Monoclonal antibody; Crohn's disease; Vedolizumab; Immunology; Trough level; Efficacy; Tumor necrosis factor alpha; Internal medicine; Pharmacology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002223489,0.0002443988,0.0002840746,0.0002854131,0.00001448267,0.00000376459,0.0001991649,0.000061835,0.0000141378],"category_scores_gemma":[0.00003991013,0.0001789148,0.00009858891,0.0001025307,0.000163888,0.00002380543,0.00006516997,0.00008361766,0.00000564642],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002160771,"about_ca_system_score_gemma":0.00007618193,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006032335,"about_ca_topic_score_gemma":0.0007429608,"domain_scores_codex":[0.9981309,0.0004266619,0.0005552206,0.0004140247,0.00008041043,0.0003927488],"domain_scores_gemma":[0.9993657,0.00002633144,0.0001400527,0.0003706162,0.00003066591,0.00006658358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005264692,0.0006104285,0.9915165,0.0001612112,0.00001393298,0.00003396473,0.00003867484,0.0001777038,0.001624015,0.00007946807,0.000007560287,0.005210048],"study_design_scores_gemma":[0.002540549,0.0001864677,0.9950871,0.001176525,0.00001415013,0.000001823221,0.00004449013,0.000006822222,0.00007751481,0.0002041226,0.0005497245,0.0001107183],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9168211,0.0820756,0.00003683624,0.0002332391,0.0002313138,0.0005519442,0.00003286389,0.000007677572,0.000009468098],"genre_scores_gemma":[0.8683503,0.1309632,0.00004541912,0.00002469813,0.00003893849,0.0005214688,0.00003176847,0.00001275261,0.00001148664],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04888762,"threshold_uncertainty_score":0.7295933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01589544296324558,"score_gpt":0.3056780486312765,"score_spread":0.2897826056680309,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}